Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

The multi-tasking, helter-skelter billionaire wants to put chips in our brains with his Neuralink company, and the FDA just gave him the go-ahead.

Fortune

Civil service unions enter new pay talks with UK government

Prospect and FDA suspend strike action after offer of ‘meaningful’ talks, with PCS also attending

The Guardian - UK

Musk's Neuralink says it won FDA approval for human trials

Elon Musk's Neuralink said it has been cleared by the FDA to begin human trials on its brain-implant technology.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Elon Musk says his Neuralink brain chips have been approved for trials on humans

Patients have been able to register their interest to enroll in tests since earlier in the year

Evening Standard

Elon Musk's 'mind control chip' is cleared for human testing despite monkey deaths

Human trials will start soon on a brain implant which aims to help treat people with autism, obesity and a range of other conditions, despite earlier rejections over animal deaths

Daily Mirror

B4 million in fake herbal products seized

Police have confiscated fake herbal products worth about 4 million baht during raids on four locations in Bangkok and Pathum Thani following an investigation into sales of the products by Chinese nationals to Chinese tourists.

Bangkok Post

Elon Musk’s Neuralink brain chip company says it now has FDA approval for human testing

Brain chip firm has reportedly killed about 1,500 animals, including over 280 sheep, pigs and, monkeys

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Elon Musk's futuristic brain chip startup Neuralink gets FDA approval for human testing that 'represents an important first step'

Musk has pitched his startup and its technology, which requires drilling into patients' skulls, as potentially helping people with paralysis.

Fortune

Why the underestimated economic burden of rare diseases could be costing the U.S. trillions of dollars

While rare diseases impact a small population, the cost to society is staggering. It may be in the range of $7.2-$8.6 trillion per year.

Fortune

A psychedelic clue to the cause of SIDS

A new study using radioactive psychedelics suggests that infants who die of SIDS have abnormal serotonin receptors

Salon

COVID pill Paxlovid gets full FDA approval after more than a year of emergency use

U.S. health regulators have given full approval to Pfizer’s COVID-19 pill Paxlovid

The Independent UK

Warning flesh-eating zombie drug could be widespread in UK after first death

It has contributed to an epidemic of drug deaths in the US

Wales Online

There’s Still Scary Stuff in Sunscreen

Endocrine disrupters and other potentially dangerous ingredients persist despite FDA concerns.

Businessweek

Analysts expect Medtronic to deliver frank financial answers this week

Medtronic is facing sluggish sales growth, is in the midst of deep cost-cutting and started ongoing global layoffs in April. It's also spinning off businesses with weaker profit margins.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

If Sen. John Cornyn is part of the ‘deep state,’ as Trump says, what exactly is the deep state?

WASHINGTON – Sen. John Cornyn earned a spot on Donald Trump’s naughty list by saying the GOP should pick someone else for president in 2024.

LiveScience

Extremely rare case of mad cow disease detected in the US

It is only the seventh case of the deadly disease reported in the U.S. since it first emerged in the country in 2003.

StockNews.com

4 Hyper-Growth Stocks That Could Soar

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

Daily Mirror

First Brit to die of flesh-eating 'zombie drug' named as dad-of-two

Karl Warburton, 43, died last May from xylazine, which is used by vets as a tranquilliser for large animals such as horses and cows - the drug has never been approved for human use as it can cause flesh-rotting sores on takers’ skin

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

‘Zombie drug’ could be widespread in UK, experts warn

Xylazine is a powerful sedative which has swept across the United States.

Daily Mirror

Brit man, 43, dies after taking notorious US 'zombie drug' in grim new UK first

A British man has become the first confirmed to have died after taking powerful drug Xylazine, dubbed the zombie drug, in the UK after dozens across the United States

Salon

GOP moves to limit abortion pill in US

A House panel advanced a 2024 budget bill that would block the ability to access the abortion drug via telehealth

Fortune

This tech CEO is swapping blood with his 17-year-old son to stay young

This CEO is going to against the better judgment of the FDA to remain youthful.

Tribune News Service

Lisa Jarvis: How to solve America’s drug shortage problem

Drug shortages in the US are forcing physicians and the public to scramble for access to vital medicines. While the problem isn’t new, the number of products in scarce supply is nearing an all-time high — and could get worse as generic drug makers pare back on the breadth of…

WEKU

A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

The Independent UK

New nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

U.S. health regulators have approved a new nasal spray to reverse overdoses due to fentanyl and other powerful opioids

1 … 137 138 139 140

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.